Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ATEZOLIZUMAB for Lung neoplasm malignant: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 1,262 adverse event reports in the FDA FAERS database where ATEZOLIZUMAB was used for Lung neoplasm malignant.

Most Reported Side Effects for ATEZOLIZUMAB

Side Effect Reports % Deaths Hosp.
Death 3,591 10.7% 3,591 457
Off label use 2,340 6.9% 769 611
Disease progression 1,828 5.4% 815 355
Pyrexia 1,599 4.7% 261 1,096
Diarrhoea 1,490 4.4% 327 798
Fatigue 1,253 3.7% 296 504
Anaemia 1,195 3.6% 237 695
Pneumonia 1,036 3.1% 382 698
Nausea 953 2.8% 219 498
Dyspnoea 938 2.8% 290 614
Decreased appetite 928 2.8% 233 436
Hypothyroidism 881 2.6% 114 202
Febrile neutropenia 872 2.6% 148 641
Pneumonitis 842 2.5% 243 416
Asthenia 821 2.4% 262 389

Other Indications for ATEZOLIZUMAB

Hepatocellular carcinoma (8,443) Non-small cell lung cancer (4,459) Small cell lung cancer (2,107) Product used for unknown indication (1,888) Small cell lung cancer extensive stage (1,398) Triple negative breast cancer (1,393) Lung adenocarcinoma (1,032) Non-small cell lung cancer metastatic (870) Transitional cell carcinoma (788) Ovarian cancer (519)

Other Drugs Used for Lung neoplasm malignant

ERLOTINIB (9,207) OSIMERTINIB (4,754) NIVOLUMAB (4,197) PEMBROLIZUMAB (3,575) CARBOPLATIN (3,487) ALECTINIB (2,932) PEMETREXED (2,422) CRIZOTINIB (1,949) BEVACIZUMAB (1,810) PACLITAXEL (1,747)

Related Pages

ATEZOLIZUMAB Full Profile All Lung neoplasm malignant Drugs ATEZOLIZUMAB Demographics ATEZOLIZUMAB Timeline